

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM460053

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Aquestive Therapeutics, Inc.	FORMERLY MonoSol Rx, LLC	01/30/2018	Corporation: DELAWARE
MonoSol Rx, Inc.		01/30/2018	Corporation: DELAWARE
MSRX US, LLC		01/30/2018	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	PERCEPTIVE CREDIT HOLDINGS, LP		
Street Address:	51 Astor Place, 10th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10003		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 23			
Property Type	Number	Word Mark	
Serial Number:	87719576	A	
Serial Number:	87492329	LIBERVANT	
Serial Number:	87163393	ALLERFILM	
Serial Number:	87595759	EXORDIA	
Serial Number:	87512075	EXSERVAN	
Serial Number:	87492332	SYMPAZAN	
Serial Number:	87458573	SSF	
Serial Number:	87458567	OSF	
Serial Number:	87458564	BSF	
Serial Number:	87269501	DRUG DIFFERENTIATION BY DESIGN	
Serial Number:	87163388	ANAFILM	
Serial Number:	87163385	ANAPHYLM	
Serial Number:	87163370	ANEPIFILM	
Serial Number:	87163378	THEPIFILM	
Serial Number:	87139551	PALLAQUEL	
Serial Number:	87139549	EFFERVA	

CH \$590.00 87719576

Property Type	Number	Word Mark
Serial Number:	87139547	CARESTA
Serial Number:	87139543	ASPONTA
Serial Number:	86662567	AQUESTIVE
Registration Number:	3877508	ZUPLENZ
Registration Number:	3349534	
Registration Number:	3336176	MONOSOL RX
Registration Number:	3580900	PHARMFILM

CORRESPONDENCE DATA

Fax Number: 7037607777

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 703-760-7360

Email: hcheng@mofo.com

Correspondent Name: Hsiao-Ting Cheng

Address Line 1: 1650 Tyson Boulevard

Address Line 2: Suite 400

Address Line 4: McLean, VIRGINIA 22102

NAME OF SUBMITTER:	Jeffrey Xu
SIGNATURE:	/Jeffrey Xu/
DATE SIGNED:	01/30/2018

Total Attachments: 4

source=MonoSol - Amendment to Trademark Security Agreement#page1.tif

source=MonoSol - Amendment to Trademark Security Agreement#page2.tif

source=MonoSol - Amendment to Trademark Security Agreement#page3.tif

source=MonoSol - Amendment to Trademark Security Agreement#page4.tif

AMENDMENT TO TRADEMARK SECURITY AGREEMENT

This **AMENDMENT TO TRADEMARK SECURITY AGREEMENT** (this "**Amendment**"), dated as of January 30, 2018, is executed by Aquestive Therapeutics, Inc., a Delaware corporation (f/k/a MonoSol Rx, LLC) ("**Grantor**"), having its principal office at 30 Technology Drive, Warren, New Jersey, 07059, and Perceptive Credit Holdings, LP, as collateral agent (in such capacity, "**Collateral Agent**"), having its principal offices at 51 Astor Place, 10th Floor, New York, New York, 10003.

RECITALS

WHEREAS, MonoSol Rx, Inc. and MSRX US, LLC (collectively, "**Subsidiary Grantors**"), Grantor and Collateral Agent entered into a certain Security Agreement, dated as of August 16, 2016 (the "**Security Agreement**"); and

WHEREAS, in connection with the Security Agreement, Grantor, Subsidiary Grantors and Collateral Agent entered into a certain Trademark Security Agreement dated as of August 16, 2016 (the "**Agreement**"; capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement); and

WHEREAS, pursuant to the Agreement, Grantor and Subsidiary Grantors granted to Collateral Agent a security interest in Trademark Collateral; and

WHEREAS, Grantor has changed its name from MonoSol Rx, LLC to Aquestive Therapeutics, Inc. and converted from a Delaware limited liability company into a Delaware corporation; and

WHEREAS, pursuant to the Omnibus Amendment No.1 dated as of January 1, 2018 among Grantor, Lenders party thereto ("**Lenders**") and Perceptive Credit Holdings, LP, as Administrative Agent (in such capacity, "**Administrative Agent**"), Administrative Agent and Lenders have released the Subsidiary Grantors as "Subsidiary Guarantors".

NOW, THEREFORE, Collateral Agent and Grantor agree as follows:


1. The Agreement is amended replacing **Schedule 1** with the attached **Schedule 1**.
2. Collateral Agent may record this Amendment with the PTO, at the expense of Grantor.
3. Subsidiary Grantors are released from the Agreement.
4. Except as herein expressly amended and supplemented, all of the terms and provisions of the Agreement shall continue in full force and effect and the same are hereby ratified and confirmed.
5. Each reference in the Agreement to MonoSol Rx, LLC shall be deemed to refer to Aquestive Therapeutics, Inc.
6. This Amendment and the rights and obligations of the parties under this Amendment shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties have executed this Amendment on the date first written above.

GRANTOR:

**AQUESTIVE THERAPEUTICS, INC. (f/ka
MonoSol Rx, LLC)**


By  _____
Name: John Maxwell
Title: CFO

Accepted and Agreed:

**PERCEPTIVE CREDIT HOLDINGS, LP, as
Collateral Agent**

**By Perceptive Credit Opportunities GP, LLC, its
general partner**

By: 
Name: Sandeep Dixit
Title: Chief Credit Officer

By: 
Name: Sam Chawla
Title: Portfolio Manager

SCHEDULE 1
to the Amendment to Trademark Security Agreement

TRADEMARKS

Trademark Registrations and Applications

Trademark	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
A Logo 	87719576	December 13, 2017	Aquestive Therapeutics, Inc.
LIBERVANT	87492329	June 16, 2017	Aquestive Therapeutics, Inc.
ALLERFILM	87163393	September 7, 2016	Aquestive Therapeutics, Inc.
EXORDIA	87595759	September 5, 2017	Aquestive Therapeutics, Inc.
EXSERVAN	87512075	June 30, 2017	Aquestive Therapeutics, Inc.
SYMPAZAN	87492332	June 16, 2017	Aquestive Therapeutics, Inc.
SSF	87458573	May 22, 2017	Aquestive Therapeutics, Inc.
OSF	87458567	May 22, 2017	Aquestive Therapeutics, Inc.
BSF	87458564	May 22, 2017	Aquestive Therapeutics, Inc.
DRUG DIFFERENTIATION BY DESIGN	87269501	December 15, 2016	Aquestive Therapeutics, Inc.
ANAFILM	87163388	September 7, 2016	Aquestive Therapeutics, Inc.
ANAPHYLM	87163385	September 7, 2016	Aquestive Therapeutics, Inc.
ANEPIFILM	87163370	September 7, 2016	Aquestive Therapeutics, Inc.
THEPIFILM	87163378	September 7, 2016	Aquestive Therapeutics, Inc.
PALLAQUEL	87139551	August 16, 2016	Aquestive Therapeutics, Inc.
EFFERVA	87139549	August 16, 2016	Aquestive Therapeutics, Inc.
CARESTA	87139547	August 16, 2016	Aquestive Therapeutics, Inc.
ASPONTA	87139543	August 16, 2016	Aquestive Therapeutics, Inc.
AQUESTIVE	86662567	June 15, 2015	Aquestive Therapeutics, Inc.
ZUPLENZ	3,877,508	November 16, 2010	Aquestive Therapeutics, Inc.
Miscellaneous Design 	3,349,534	December 4, 2007	Aquestive Therapeutics, Inc.
MONOSOL RX	3,336,176	November 13, 2007	Aquestive Therapeutics, Inc.
PHARMFILM	3,580,900	February 24, 2009	Aquestive Therapeutics, Inc.